title: Azithromycin for the secondary prevention of coronary events.
abstract: BACKGROUND
  Epidemiologic, laboratory, animal, and clinical studies suggest that there is an association between Chlamydia pneumoniae infection and atherogenesis. We evaluated the efficacy of one year of azithromycin treatment for the secondary prevention of coronary events.
  
  
  METHODS
  In this randomized, prospective trial, we assigned 4012 patients with documented stable coronary artery disease to receive either 600 mg of azithromycin or placebo weekly for one year. The participants were followed for a mean of 3.9 years at 28 clinical centers throughout the United States.
  
  
  RESULTS
  The primary end point, a composite of death due to coronary heart disease, nonfatal myocardial infarction, coronary revascularization, or hospitalization for unstable angina, occurred in 446 of the participants who had been randomly assigned to receive azithromycin and 449 of those who had been randomly assigned to receive placebo. There was no significant risk reduction in the azithromycin group as compared with the placebo group with regard to the primary end point (risk reduction, 1 percent [95 percent confidence interval, -13 to 13 percent]). There were also no significant risk reductions with regard to any of the components of the primary end point, death from any cause, or stroke. The results did not differ when the participants were stratified according to sex, age, smoking status, presence or absence of diabetes mellitus, or C. pneumoniae serologic status at baseline.
  
  
  CONCLUSIONS
  A one-year course of weekly azithromycin did not alter the risk of cardiac events among patients with stable coronary artery disease.
authors.affiliation: Department of Epidemiology, University of Washington, Seattle 98195, USA.
authors.forename: J Thomas
authors.initials: JT
authors.lastname: Grayston
authors.forename: Richard A
authors.initials: RA
authors.lastname: Kronmal
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Jackson
authors.forename: Alfred F
authors.initials: AF
authors.lastname: Parisi
authors.forename: Joseph B
authors.initials: JB
authors.lastname: Muhlestein
authors.forename: Jerome D
authors.initials: JD
authors.lastname: Cohen
authors.forename: William J
authors.initials: WJ
authors.lastname: Rogers
authors.forename: John R
authors.initials: JR
authors.lastname: Crouse
authors.forename: Sandra L
authors.initials: SL
authors.lastname: Borrowdale
authors.forename: Eleanor
authors.initials: E
authors.lastname: Schron
authors.forename: Charles
authors.initials: C
authors.lastname: Knirsch
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017963:Azithromycin / Q000009:adverse effects / Q000627:therapeutic use*; D023521:Chlamydophila Infections / Q000188:drug therapy; D016993:Chlamydophila pneumoniae; D003327:Coronary Disease / Q000188:drug therapy* / Q000401:mortality / Q000517:prevention & control; D004311:Double-Blind Method; D005260:Female; D034381:Hearing Loss / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control*; D009204:Myocardial Revascularization; D011446:Prospective Studies
chemical_list: D000900:Anti-Bacterial Agents; D017963:Azithromycin